Related Experiment Video
Updated: Apr 30, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Inhibitors - genetic and environmental factors
D Lillicrap1, K Fijnvandraat, E Santagostino
1Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, ON, Canada.
Understanding factor VIII (FVIII) inhibitors in haemophilia A is complex. Research using animal models and clinical data explores FVIII immunogenicity and tolerance induction, crucial for managing this rare complication.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Inhibitor development against factor VIII (FVIII) in haemophilia A is influenced by genetic and environmental factors, with underlying mechanisms still under investigation.
- Clinical research is challenging due to the infrequent occurrence of inhibitors in this rare disease.
- Animal models, particularly mouse models, are vital for studying FVIII immunogenicity, immune responses, and tolerance induction strategies.
Purpose of the Study:
- To investigate the pathogenetic mechanisms of inhibitor development towards factor VIII (FVIII).
- To explore the role of FVIII product type and product switching in inhibitor development.
- To provide insights into FVIII immunogenicity and tolerance induction using complementary animal studies.
Main Methods:
- Review and evaluation of existing literature on FVIII inhibitor development.
- Analysis of data concerning the influence of different FVIII products (recombinant vs. plasma-derived, full length vs. B-domainless) on immunogenicity.
- Examination of clinical data related to product switching and its association with inhibitor risk.
- Utilisation of mouse models to study FVIII immunogenicity and tolerance induction.
Main Results:
- Current literature does not unequivocally demonstrate differences in immunogenicity among various FVIII products.
- National product switches have not been associated with an increased risk of inhibitor development.
- While the inhibitor risk is low in moderate and mild haemophilia A, it persists lifelong, especially after intensive FVIII exposure.
Conclusions:
- Complementary studies, including those with animal models, are essential for understanding FVIII inhibitor pathogenesis and treatment.
- The type of FVIII product and product switching do not appear to be definitive factors in inhibitor development based on current evidence.
- Continuous vigilance is necessary for patients with moderate and mild haemophilia A due to the lifelong, albeit low, risk of inhibitor development.
More Related Videos
09:13Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice
Published on: July 11, 2025
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Gene-Environment Interactions
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Enzyme Inhibition
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Inhibitors of Viral Protein Synthesis